Begin Phase 2b trial of miricorilant
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 May 2023
- Due
- 31 Dec 2023
- Delivered
- October 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Phase 2b trial to begin in the fourth quarter”
What we found
Evidence strength A What the grades mean
The company initiated the Phase 2b trial of miricorilant, known as MONARCH, in October 2023, which falls within the fourth quarter deadline.
-
A Corcept Therapeutics Inc. 10-K filed 2024-02-15
“we initiated a Phase 2b trial (“MONARCH”) of miricorilant in patients with NASH in October 2023.” ✓ confirmed on the page
Market reaction: the shares moved -6.3% against the S&P 500 over the three sessions around the disclosure (14 Feb 2024 to 20 Feb 2024). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- Phase 2b miricorilant trial
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Corcept Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-CORT-002876 · Corrections policy